capecitabine has been researched along with Cells, Neoplasm Circulating in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Friberg, LE; Karlsson, MO; Koopman, M; Netterberg, I; Punt, CJA; Terstappen, LWMM | 1 |
| Cai, R; Chen, S; Fan, Y; Guan, X; Hu, S; Huang, J; Li, C; Li, Q; Luo, Y; Ma, F; Sun, X; Wang, J; Wu, S; Xu, B; Zhang, P | 1 |
| de Stanchina, E; Fleisher, M; Kemeny, MM; Li, BT; Morikawa, A; Norton, L; Patil, S; Pentsova, E; Seidman, AD; Tang, K; Van Poznak, C | 1 |
| Abad, A; Aranda, E; Benavides, M; Gallen, M; Gómez, A; López, MR; Massutí, B; Rivera, F; Rubio, ED; Sastre, J; Vidaurreta, M | 1 |
| Bachelot, T; Bidard, FC; Campone, M; Cropet, C; Curé, H; Dalenc, F; Dômont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Mahier Aït-Oukhatar, C; Pierga, JY; Romieu, G; Tresca, P | 1 |
| Abal, M; Barbazán, J; Candamio, S; Cano, A; Casares de Cal, Mde L; Díaz-López, A; Gómez-Tato, A; López-López, R; Muinelo-Romay, L; Vieito, M | 1 |
| Ashcroft, L; Backen, A; Beech, J; Chau, I; Dive, C; Gollins, S; Hasan, J; Krebs, MG; Morris, K; Renehan, AG; Saunders, MP; Valle, JW | 1 |
| Hu, YF; Li, FP; Li, GX; Li, TT; Lin, T; Liu, H; Mou, TY; Yu, J; Zheng, L | 1 |
| Cao, Y; Gao, J; Gong, J; Li, Y; Lu, Z; Shen, L; Zhang, Q | 1 |
| Beeker, A; Beerepoot, LV; Beijnen, JH; Boers, JE; Cats, A; de Groot, JW; de Jong, RS; Goey, SH; Grootscholten, C; Kuiper, M; Los, M; Meulendijks, D; Pluim, D; Polee, MB; Portielje, JE; Schellens, JH; Sikorska, K; Tesselaar, ME; Vanhoutvin, SA | 1 |
| Cats, A; Creemers, GJ; Koopman, M; Miller, MC; Nagtegaal, ID; Punt, CJ; Terstappen, LW; Tibbe, A; Tol, J; Vos, AH | 1 |
| Eidtmann, H; Fehm, T; Hilfrich, J; Holms, F; Huober, J; Komor, M; Loibl, S; Müller, V; Pantel, K; Rau, T; Riethdorf, S; Roller, M; Schrader, I; Tesch, H; Untch, M; von Minckwitz, G; Zhang, L | 1 |
| Fusi, A; Keilholz, U; Liu, Z; Schmittel, A; Schneider, A; Tinhofer, I | 1 |
| Abad, A; Aranda, E; Arrivi, A; Benavides, M; Díaz-Rubio, E; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Maestro, ML; Marcuello, E; Massuti, B; Rivera, F; Sastre, J; Tabernero, JM; Valladares, M; Vidaurreta, M | 1 |
| Aksu, G; Fayda, M; Kapran, Y; Sakar, B | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
8 trial(s) available for capecitabine and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoembryonic Antigen; Cell Count; Docetaxel; Epithelial-Mesenchymal Transition; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplastic Cells, Circulating; Phenotype; Prognosis; Receptor, ErbB-2; Treatment Outcome | 2019 |
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Drug Administration Schedule; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Receptor, ErbB-2; Treatment Outcome | 2019 |
Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Oxaloacetates; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate | 2015 |
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Receptor, ErbB-2; Stomach Neoplasms; Taxoids | 2016 |
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Fluorescent Antibody Technique; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2010 |
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2012 |
8 other study(ies) available for capecitabine and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cell Count; Cetuximab; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Models, Biological; Multicenter Studies as Topic; Neoplastic Cells, Circulating; Oxaliplatin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Response Evaluation Criteria in Solid Tumors; Risk Assessment; Tumor Burden | 2020 |
A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2014 |
Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Case-Control Studies; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Drug Monitoring; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Gastrectomy; Humans; In Situ Hybridization; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Oxaloacetates; Phenotype; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Esophagogastric Junction; Female; Humans; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2016 |
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Genetic Markers; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Colon cancer with isolated metastasis to the kidney at the time of initial diagnosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Kidney Neoplasms; Leucovorin; Male; Neoplastic Cells, Circulating; Nephrectomy | 2003 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |